Treatment Options for BCR After Local Therapy for Prostate Cancer

March 14, 2014
Rana R. McKay, MD

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.

Clinical Pearls

Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.

  • Biochemical relapse is a heterogenous disease state and is likely related to tumor biology
  • Classically, patients who have received a radical prostatectomy may be candidates for salvage radiation therapy with or without hormone therapies
  • Patients who initially received primary radiation therapy may be candidates for salvage radical prostatectomy or hormone therapy
  • In a previous study, patients in this space were essentially cured following treatment with docetaxel plus estramustine and ADT
  • This trial, presented at the 2014 Genitourinary Cancers Symposium, aimed to determine the benefit of docetaxel plus bevacizumab and ADT